Accession Number : ADP006561
Title : HIV Infection in the Nineties,
Corporate Author : WORLD HEALTH ORGANIZATION GENEVA (SWITZERLAND)
Personal Author(s) : Kallings, Lars O.
Report Date : APR 1992
Pagination or Media Count : 5
Abstract : Currently available vaccines include plasma-derived vaccines and yeast- derived vaccines. Plasma-derived vaccines, introduced in 1981, were the first available vaccines to provide active protection against HBV. They consist of 22 nm spherical surface antigen particles (the noninfectious excess protein coat of the virus) purified from the plasma of HBsAg carriers, subsequently inactivated and alum adjuvanted. More recently, recombinant DNA technology has been used to express HBsAg in prokaryotic as well in eukaryotic cells such as yeast cells (Saccharomyces cerevisiae) (1). Much effort has been spent devising host cells able to successfully express HBsAg, including mammalian cells, insect cells, vaccinia virus and heatoma cells. Concern has been expressed about the safety of vaccines derived from tumours cells, as well as for those employing faccinia virus as avector. The possibility of using other recombinant viruses as vectors (i.e. Adenoviruses) is being explored. Saccharomyces cerevisiae has proven to be a successful host and genetically engineered yeast-derived vaccines have been commercially available since 1986.
Descriptors : *AEROSPACE MEDICINE, *VACCINES, HUMAN IMMUNODEFICIENCY VIRUSES, DEOXYRIBONUCLEIC ACIDS, HEPATITIS, DEATH, ANTIGEN ANTIBODY REACTIONS.
Subject Categories : Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE